AOP-Wiki

API

All KERs

Showing 51 to 75 of 3002 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1865	1605: Accumulation, misfolded proteins	1512: Unfolded Protein Response	Mar 6, 2019	Mar 6, 2019	1 AOP 285: Inhibition of N-linked glycosylation leads to liver injury
3045	1605: Accumulation, misfolded proteins	2017: Endoplasmic reticulum stress	Sep 14, 2023	Sep 14, 2023	1 AOP 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits
3046	1605: Accumulation, misfolded proteins	2188: Caspase activation	Sep 14, 2023	Sep 14, 2023	1 AOP 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits
82	68: Accumulation, Collagen	344: N/A, Liver fibrosis	Nov 29, 2016	Dec 5, 2018	2 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis
1629	68: Accumulation, Collagen	1458: Pulmonary fibrosis	Jul 26, 2017	May 18, 2023	2 AOPs 241: Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis 173: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis
2139	68: Accumulation, Collagen	1276: Lung fibrosis	May 15, 2020	May 15, 2020	2 AOPs 382: Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis 319: Binding to ACE2 leading to lung fibrosis
2503	1942: Accumulation, Toxic Tau oligomers	1582: Impaired axonial transport	Oct 26, 2021	Oct 26, 2021	1 AOP 429: A cholesterol/glucose dysmetabolism initiated Tau-driven AOP toward memory loss (AO) in sporadic Alzheimer's Disease with plausible MIE's plug-ins for environmental neurotoxicants
2507	1942: Accumulation, Toxic Tau oligomers	188: Neuroinflammation	Oct 26, 2021	Oct 26, 2021	1 AOP 429: A cholesterol/glucose dysmetabolism initiated Tau-driven AOP toward memory loss (AO) in sporadic Alzheimer's Disease with plausible MIE's plug-ins for environmental neurotoxicants
662	570: Accumulation, Damaged mitochondrial DNA	571: Accelerated, Aging	Nov 29, 2016	Dec 3, 2016	1 AOP 80: Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure
472	327: Accumulation, Fatty acid	291: Accumulation, Triglyceride	Nov 29, 2016	May 28, 2024	1 AOP 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis
514	327: Accumulation, Fatty acid	454: Increased, Triglyceride formation	Nov 29, 2016	Dec 3, 2016	1 AOP 58: NR1I3 (CAR) suppression leading to hepatic steatosis
515	327: Accumulation, Fatty acid	459: Increased, Liver Steatosis	Nov 29, 2016	Dec 3, 2016	4 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 36: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 57: AhR activation leading to hepatic steatosis
866	846: Accumulation, Highly carboxylated porphyrins	369: Uroporphyria	Nov 29, 2016	May 7, 2018	1 AOP 131: Aryl hydrocarbon receptor activation leading to uroporphyria
2265	291: Accumulation, Triglyceride	459: Increased, Liver Steatosis	Jan 15, 2021	Mar 27, 2024	6 AOPs 318: Glucocorticoid Receptor activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis 518: Liver X Receptor (LXR) activation leads to liver steatosis 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis 57: AhR activation leading to hepatic steatosis 591: DBEPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration
3162	291: Accumulation, Triglyceride	177: Mitochondrial dysfunction	Mar 13, 2024	Mar 13, 2024	1 AOP 34: LXR activation leading to hepatic steatosis
3544	291: Accumulation, Triglyceride	2332: Increase, Lipid droplet	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
3548	291: Accumulation, Triglyceride	2334: Increase, DGAT1	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
2524	1938: ACE2 increased shedding	1935: Ang (1-7) levels reduced	Oct 28, 2021	Oct 28, 2021	None
454	10: ACh Synaptic Accumulation	444: Increased, Atrioventricular block and bradycardia	Nov 29, 2016	Nov 29, 2016	None
456	10: ACh Synaptic Accumulation	39: Increased Cholinergic Signaling	Nov 29, 2016	Dec 20, 2019	3 AOPs 16: Acetylcholinesterase inhibition leading to acute mortality 312: Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement 405: Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function
459	10: ACh Synaptic Accumulation	12: AchE Inhibition	Nov 29, 2016	Dec 3, 2016	1 AOP 471: Various neuronal effects induced by elavl3, sox10, and mbp
1857	10: ACh Synaptic Accumulation	1602: Activation, Muscarinic Acetylcholine Receptors	Feb 13, 2019	Sep 3, 2023	1 AOP 281: Acetylcholinesterase Inhibition Leading to Neurodegeneration
11	12: AchE Inhibition	10: ACh Synaptic Accumulation	Nov 29, 2016	Sep 10, 2023	4 AOPs 16: Acetylcholinesterase inhibition leading to acute mortality 281: Acetylcholinesterase Inhibition Leading to Neurodegeneration 312: Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement 405: Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function
449	12: AchE Inhibition	444: Increased, Atrioventricular block and bradycardia	Nov 29, 2016	Dec 3, 2016	None
450	12: AchE Inhibition	445: Respiratory distress/arrest	Nov 29, 2016	Dec 20, 2019	1 AOP 16: Acetylcholinesterase inhibition leading to acute mortality

Key Event Relationships (KERs)

All KERs